Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Dae Hyun Kim, Sc.D., M.D.

Co-Author

This page shows the publications co-authored by Dae Hyun Kim and L. Wei.
Connection Strength

8.226
  1. Restricted mean survival time versus conventional measures for treatment decision-making. J Am Geriatr Soc. 2021 08; 69(8):2282-2289.
    View in: PubMed
    Score: 0.933
  2. Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results. JAMA Cardiol. 2017 11 01; 2(11):1179-1180.
    View in: PubMed
    Score: 0.733
  3. Quantifying and Interpreting Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Cancer Control for Advanced Gastroesophageal Cancer Among an Older Population. JAMA Oncol. 2021 11 01; 7(11):1723-1724.
    View in: PubMed
    Score: 0.242
  4. Moving beyond conventional stratified analysis to assess the treatment effect in a comparative oncology study. J Immunother Cancer. 2021 11; 9(11).
    View in: PubMed
    Score: 0.242
  5. Intensive versus standard blood pressure control in type 2 diabetes: a restricted mean survival time analysis of a randomised controlled trial. BMJ Open. 2021 09 13; 11(9):e050335.
    View in: PubMed
    Score: 0.240
  6. Survival Analysis of Treatment Efficacy in Comparative Coronavirus Disease 2019 Studies. Clin Infect Dis. 2021 06 01; 72(11):e887-e889.
    View in: PubMed
    Score: 0.235
  7. Utility of Restricted Mean Survival Time for Analyzing Time to Nursing Home Placement Among Patients With Dementia. JAMA Netw Open. 2021 01 04; 4(1):e2034745.
    View in: PubMed
    Score: 0.228
  8. Further clinical interpretation and implications of KEYNOTE-048 findings. Lancet. 2020 08 08; 396(10248):378-379.
    View in: PubMed
    Score: 0.222
  9. Risk-Benefit Comparisons Between Shorter and Longer Durations of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer. JAMA Oncol. 2020 08 01; 6(8):1301-1302.
    View in: PubMed
    Score: 0.222
  10. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. 2020 09 03; 383(10):993.
    View in: PubMed
    Score: 0.221
  11. Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies. Ann Intern Med. 2020 09 01; 173(5):368-374.
    View in: PubMed
    Score: 0.221
  12. How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19. Ann Intern Med. 2020 10 20; 173(8):632-637.
    View in: PubMed
    Score: 0.221
  13. Analysis of Overall Survival Benefit of Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer. JAMA Oncol. 2020 07 01; 6(7):1121-1122.
    View in: PubMed
    Score: 0.220
  14. Fulvestrant plus capivasertib for metastatic breast cancer. Lancet Oncol. 2020 05; 21(5):e233.
    View in: PubMed
    Score: 0.218
  15. Assessment of Treatment Effect With Multiple Outcomes in 2 Clinical Trials of Patients With Duchenne Muscular Dystrophy. JAMA Netw Open. 2020 02 05; 3(2):e1921306.
    View in: PubMed
    Score: 0.214
  16. Using Confidence Intervals to Quantify Statistical and Clinical Evidence for the Treatment Effect in a Comparative Study-Moving Beyond P Values. JAMA Otolaryngol Head Neck Surg. 2020 01 01; 146(1):5-6.
    View in: PubMed
    Score: 0.213
  17. Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes. JNCI Cancer Spectr. 2019 Dec; 3(4):pkz058.
    View in: PubMed
    Score: 0.207
  18. Comment on "Interpreting Clinical Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer (BRPC)". Ann Surg. 2019 08; 270(2):e48-e50.
    View in: PubMed
    Score: 0.207
  19. Analysis of Long-term Benefits of Intensive Blood Pressure Control. JAMA. 2019 07 09; 322(2):169-170.
    View in: PubMed
    Score: 0.206
  20. Biodegradable-polymer stents versus durable-polymer stents. Lancet. 2019 05 11; 393(10184):1932-1933.
    View in: PubMed
    Score: 0.204
  21. Effects of Aspirin in the Healthy Elderly. N Engl J Med. 2019 05 02; 380(18):1775-1776.
    View in: PubMed
    Score: 0.203
  22. Interpreting the Prognostic Value of Unrecognized Myocardial Infarction Among Older Adults. JAMA Cardiol. 2019 04 01; 4(4):391.
    View in: PubMed
    Score: 0.202
  23. Evaluating Treatment Effect of Transcatheter Interatrial Shunt Device Using Heart Failure Event Rates. JAMA Cardiol. 2019 03 01; 4(3):299.
    View in: PubMed
    Score: 0.201
  24. Trifluridine/tipiracil in metastatic gastric cancer. Lancet Oncol. 2019 01; 20(1):e8.
    View in: PubMed
    Score: 0.199
  25. Quantifying Immunoscore performance. Lancet. 2018 11 03; 392(10158):1624.
    View in: PubMed
    Score: 0.196
  26. Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer. N Engl J Med. 2018 Oct 25; 379(17):1681.
    View in: PubMed
    Score: 0.196
  27. Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis. J Am Geriatr Soc. 2018 10; 66(10):1987-1991.
    View in: PubMed
    Score: 0.195
  28. Interpreting the Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma. JAMA Oncol. 2018 08 01; 4(8):1135-1136.
    View in: PubMed
    Score: 0.193
  29. Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study. JAMA Oncol. 2018 06 01; 4(6):874-876.
    View in: PubMed
    Score: 0.191
  30. Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study. JAMA Oncol. 2018 06 01; 4(6):881-882.
    View in: PubMed
    Score: 0.191
  31. Adding a new analytical procedure with clinical interpretation in the tool box of survival analysis. Ann Oncol. 2018 05 01; 29(5):1092-1094.
    View in: PubMed
    Score: 0.190
  32. Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing Risks. JAMA Cardiol. 2018 04 01; 3(4):357-358.
    View in: PubMed
    Score: 0.189
  33. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio. JAMA Oncol. 2017 12 01; 3(12):1692-1696.
    View in: PubMed
    Score: 0.184
  34. Applying Evidence-Based Medicine to Shared Decision Making: Value of Restricted MeanSurvival Time. Am J Med. 2019 01; 132(1):13-15.
    View in: PubMed
    Score: 0.048
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.